Stephan Kadauke1, Regina M Myers2,3, Yimei Li4, Richard Aplenc2,3, Diane Baniewicz2, David M Barrett2,3, Allison Barz Leahy2,3, Colleen Callahan2, Joseph G Dolan2,3, Julie C Fitzgerald5, Whitney Gladney6, Simon F Lacey7, Hongyan Liu4, Shannon L Maude2,3, Regina McGuire2, Laura S Motley2, David T Teachey2,3, Gerald B Wertheim1, Lisa Wray2,3, Amanda M DiNofia2,3, Stephan A Grupp1,2,3. 1. Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Cellular Therapy and Transplant Section and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA. 3. Division of Oncology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 4. Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 5. Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA. 6. Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 7. Abramson Cancer Center and Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE: To prospectively evaluate the effectiveness of risk-adapted preemptive tocilizumab (PT) administration in preventing severe cytokine release syndrome (CRS) after CTL019, a CD19 chimeric antigen receptor T-cell therapy. METHODS: Children and young adults with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia were assigned to high- (≥ 40%) or low- (< 40%) tumor burden cohorts (HTBC or LTBC) based on a bone marrow aspirate or biopsy before infusion. HTBC patients received a single dose of tocilizumab (8-12 mg/kg) after development of high, persistent fevers. LTBC patients received standard CRS management. The primary end point was the frequency of grade 4 CRS (Penn scale), with an observed rate of ≤ 5 of 15 patients in the HTBC pre-defined as clinically meaningful. In post hoc analyses, the HTBC was compared with a historical cohort of high-tumor burden patients from the initial phase I CTL019 trial. RESULTS: The primary end point was met. Seventy patients were infused with CTL019, 15 in the HTBC and 55 in the LTBC. All HTBC patients received the PT intervention. The incidence of grade 4 CRS was 27% (95% CI, 8 to 55) in the HTBC and 3.6% (95% CI, 0.4 to 13) in the LTBC. The best overall response rate was 87% in the HTBC and 100% in the LTBC. Initial CTL019 expansion was greater in the HTBC than the LTBC (P < .001), but persistence was not different (P = .73). Event-free and overall survival were worse in the HTBC (P = .004, P < .001, respectively). In the post hoc analysis, grade 4 CRS was observed in 27% versus 50% of patients in the PT and prior phase I cohorts, respectively (P = .18). CONCLUSION: Risk-adapted PT administration resulted in a decrease in the expected incidence of grade 4 CRS, meeting the study end point, without adversely impacting the antitumor efficacy or safety of CTL019.
PURPOSE: To prospectively evaluate the effectiveness of risk-adapted preemptive tocilizumab (PT) administration in preventing severe cytokine release syndrome (CRS) after CTL019, a CD19 chimeric antigen receptor T-cell therapy. METHODS: Children and young adults with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia were assigned to high- (≥ 40%) or low- (< 40%) tumor burden cohorts (HTBC or LTBC) based on a bone marrow aspirate or biopsy before infusion. HTBC patients received a single dose of tocilizumab (8-12 mg/kg) after development of high, persistent fevers. LTBC patients received standard CRS management. The primary end point was the frequency of grade 4 CRS (Penn scale), with an observed rate of ≤ 5 of 15 patients in the HTBC pre-defined as clinically meaningful. In post hoc analyses, the HTBC was compared with a historical cohort of high-tumor burden patients from the initial phase I CTL019 trial. RESULTS: The primary end point was met. Seventy patients were infused with CTL019, 15 in the HTBC and 55 in the LTBC. All HTBC patients received the PT intervention. The incidence of grade 4 CRS was 27% (95% CI, 8 to 55) in the HTBC and 3.6% (95% CI, 0.4 to 13) in the LTBC. The best overall response rate was 87% in the HTBC and 100% in the LTBC. Initial CTL019 expansion was greater in the HTBC than the LTBC (P < .001), but persistence was not different (P = .73). Event-free and overall survival were worse in the HTBC (P = .004, P < .001, respectively). In the post hoc analysis, grade 4 CRS was observed in 27% versus 50% of patients in the PT and prior phase I cohorts, respectively (P = .18). CONCLUSION: Risk-adapted PT administration resulted in a decrease in the expected incidence of grade 4 CRS, meeting the study end point, without adversely impacting the antitumor efficacy or safety of CTL019.
Authors: Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245
Authors: Rebecca A Gardner; Olivia Finney; Colleen Annesley; Hannah Brakke; Corinne Summers; Kasey Leger; Marie Bleakley; Christopher Brown; Stephanie Mgebroff; Karen S Kelly-Spratt; Virginia Hoglund; Catherine Lindgren; Assaf P Oron; Daniel Li; Stanley R Riddell; Julie R Park; Michael C Jensen Journal: Blood Date: 2017-04-13 Impact factor: 22.113
Authors: Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney Journal: J Clin Invest Date: 2016-04-25 Impact factor: 14.808
Authors: Noelle V Frey; Pamela A Shaw; Elizabeth O Hexner; Edward Pequignot; Saar Gill; Selina M Luger; James K Mangan; Alison W Loren; Alexander E Perl; Shannon L Maude; Stephan A Grupp; Nirav N Shah; Joan Gilmore; Simon F Lacey; Jos J Melenhorst; Bruce L Levine; Carl H June; David L Porter Journal: J Clin Oncol Date: 2019-12-09 Impact factor: 44.544
Authors: Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall Journal: Blood Date: 2014-05-29 Impact factor: 22.113
Authors: Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp Journal: N Engl J Med Date: 2018-02-01 Impact factor: 91.245
Authors: Rebecca A Gardner; Francesco Ceppi; Julie Rivers; Colleen Annesley; Corinne Summers; Agne Taraseviciute; Juliane Gust; Kasey J Leger; Katherine Tarlock; Todd M Cooper; Olivia C Finney; Hannah Brakke; Daniel H Li; Julie R Park; Michael C Jensen Journal: Blood Date: 2019-12-12 Impact factor: 25.476
Authors: Robert Q Le; Liang Li; Weishi Yuan; Stacy S Shord; Lei Nie; Bahru A Habtemariam; Donna Przepiorka; Ann T Farrell; Richard Pazdur Journal: Oncologist Date: 2018-04-05
Authors: Kevin J Curran; Steven P Margossian; Nancy A Kernan; Lewis B Silverman; David A Williams; Neerav Shukla; Rachel Kobos; Christopher J Forlenza; Peter Steinherz; Susan Prockop; Farid Boulad; Barbara Spitzer; Maria I Cancio; Jaap Jan Boelens; Andrew L Kung; Yasmin Khakoo; Victoria Szenes; Jae H Park; Craig S Sauter; Glenn Heller; Xiuyan Wang; Brigitte Senechal; Richard J O'Reilly; Isabelle Riviere; Michel Sadelain; Renier J Brentjens Journal: Blood Date: 2019-12-26 Impact factor: 22.113
Authors: Regina M Myers; Agne Taraseviciute; Seth M Steinberg; Adam J Lamble; Jennifer Sheppard; Bonnie Yates; Alexandra E Kovach; Brent Wood; Michael J Borowitz; Maryalice Stetler-Stevenson; Constance M Yuan; Vinodh Pillai; Toni Foley; Perry Chung; Lee Chen; Daniel W Lee; Colleen Annesley; Amanda DiNofia; Stephan A Grupp; Samuel John; Deepa Bhojwani; Patrick A Brown; Theodore W Laetsch; Lia Gore; Rebecca A Gardner; Susan R Rheingold; Michael A Pulsipher; Nirali N Shah Journal: J Clin Oncol Date: 2021-11-12 Impact factor: 44.544
Authors: Jonas W Ravich; Sujuan Huang; Yinmei Zhou; Patrick Brown; Ching-Hon Pui; Hiroto Inaba; Cheng Cheng; Stephen Gottschalk; Brandon M Triplett; Challice L Bonifant; Aimee C Talleur Journal: Transplant Cell Ther Date: 2021-12-04
Authors: Uri Greenbaum; Paolo Strati; Rima M Saliba; Janet Torres; Gabriela Rondon; Yago Nieto; Chitra Hosing; Samer A Srour; Jason Westin; Luis E Fayad; Hun J Lee; Swaminathan P Iyer; Ranjit Nair; Loretta J Nastoupil; Simrit Parmar; Maria A Rodriguez; Felipe Samaniego; Raphael E Steiner; Michael Wang; Chelsea C Pinnix; Christopher R Flowers; Sudhakar Tummala; Jeremy L Ramdial; Fevzi F Yalniz; Misha Hawkins; Katayoun Rezvani; Richard E Champlin; Elizabeth J Shpall; Sattva S Neelapu; Partow Kebriaei; Sairah Ahmed Journal: Blood Adv Date: 2021-07-27